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Retrospective analysis of patients
for development of nephrogenic systemic
fibrosis following conventional angiography
using gadolinium-based contrast agents
Abstract Purpose: The purpose was
to retrospectively review the data of
27 patients with renal insufficiency
who underwent conventional angiog-
raphy with gadolinium-based contrast
agents (GDBCA) as alternative con-
trast agents and assess the occurrence
of nephrogenic systemic fibrosis
(NSF) together with associated po-
tential risk factors. Methods: This
HIPAA-compliant study had institu-
tional review board approval, and
informed consent was waived. Statis-
tical analysis was performed for all
available laboratory and clinical data,
including dermatology reports. Type
and amount of the GDBCA used were
recorded for angiography and addi-
tional MRI studies, if applicable.
Serum creatinine levels (SCr) pre- and
post-angiography were recorded, and
estimated glomerular filtration rates
(eGFR) were calculated. Results:
Ten female and 17 male patients who
underwent angiography with GDBCA
were included. The mean amount of
GDBCA administered was 44±
15.5 ml (range 15–60 ml) or 0.24+
0.12 mmol/kg (range 0.1–0.53 mmol/
kg). At the time of angiography all
patients had renal insufficiency
(eGFR <60 ml/min/1.73 m2). Mean
eGFR pre-angiography was 26 ml/
min/1.73 m2 and 33 ml/min/1.73 m2
post-angiography. The mean follow-
up period covers 28 months, range 1–
84 months. Additional MRI studies
with GDBCA administration were
performed in 15 patients. One patient
with typical skin lesions had devel-
oped biopsy-confirmed NSF.
Conclusion: Conventional arterial
angiography with GDBCA may play
a role in the development of NSF in
patients with renal insufficiency.
Alternative contrast agents, such as
CO2 angiography or rather the use of
low doses of iodinated contrast
agents, should be considered in these
patients.
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Introduction
It is well known that the use of iodinated contrast material
may induce nephropathy, especially in patients with under-
lying renal insufficiency [1]. In the past, gadolinium-based
contrast agents (GDBCA) were used as alternative
contrast agents for conventional angiography in patients
with renal insufficiency on an off-label basis, although the
Contrast Media Safety Committee (CMSC) of the
European Society of Urogenital Radiology (ESUR) did
not approve GDBCA for radiographic examinations
[2, 3]. In a previous study, it was concluded that
angiography and percutaneous treatment of renal artery
stenosis in patients with chronic renal insufficiency and
suspected ischaemic nephropathy can be performed safely
using intra-arterial injections of GDBCA as contrast
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media without an increased risk of complications.
Contrast-induced nephropathy potentially occurred in no
more than 3.2% of patients [4]. It was further noted that
neither the degree of underlying renal insufficiency nor
diabetes was a risk factor for predicting a greater
likelihood of renal function impairment at 48-h follow-
up [4].
Recently, an illness called nephrogenic systemic fibrosis
(NSF) or nephrogenic fibrosing dermopathy was described
in patients with renal impairment presenting with typical
skin lesions and joint disease [5]. Fulminate progression
with systemic complications and autopsy reports even
suggested that NSF is a systemic disorder that may involve
other organs resulting in severe damage or even death [6, 7].
Of interest, a strong relationship between administration of
GDBCA and an outbreak of NSF was suggested by various
reports in the literature [8–10]. Even though it has not been
proven that gadolinium is the triggering agent, gadolinium
administration could be established in most NSF cases.
The purpose of this study was to retrospectively review
clinical and laboratory data of 27 patients with renal
insufficiency who underwent conventional angiography
with GDBCA as alternate contrast media and assess for the
occurrence of NSF.
Materials and methods
Patients
This HIPPA-compliant study was approved by our
institutional review board, and informed consent was
waived. As of February 2007, we retrospectively analysed
data of 27 consecutive patients (10 women and 17 men,
median age 77 years, age range 20–97 years) who had
received GDBCA as an alternative contrast agent for
conventional angiography between June 2000 and January
2002 on an off-label basis. Of those, 17 patients also
received CO2 and 13 patients also received iodinated
contrast material, including 8 patients who received both
CO2 and iodinated contrast material. All patients were pre-
and post-hydrated intravenously with 1 l of saline solution
(0.9%) each time.
Data collection
In the 27 patients, all available clinical and laboratory data
were collected. Patient’s primary care physicians were
called to collect the most recent patient information. Data
collected included age, gender, type and date of angiog-
raphy and intervention, type and amount of contrast
material administered, additional MRI studies with contrast
administration, signs of NSF noted on the chart including
dermatology reports and biopsy results, relevant co-
morbidities, cause and stage of kidney disease, and
dialysis/kidney transplant status. Skin biopsies were
stained with haematoxylin and eosin and immunohisto-
chemistry with CD 34 and CD 68 antibodies, both
characteristic of NSF. The laboratory values examined
included serum creatinine (sCr) levels pre- and post-
angiography, and estimated glomerular filtration rates
(eGFR). Based on the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative, kidney disease was
staged as follows: stage 1: eGFR >90 ml/min/1.73 m2,
stage 2: eGFR 60–90 ml/min/1.73 m2, stage 3: 30–59 ml/
min/1.73 m2, stage 4: 15–29 ml/min/1.73 m2 and stage
5: <15 ml/min/1.73 m2.
Statistical analysis
The age and gender distribution of patients was calculated
using descriptive statistics. Mean, standard deviation and
range were calculated for the amount of gadolinium
administered during angiography, serum creatinine values
and eGFR. Analysis was performed with GraphPad
statistical software (Prism v. 4.01 and InStat v 3.0;
GraphPad Software, San Diego, CA).
Results
Results are summarised in Tables 1 and 2. Twenty-five
patients received low-osmolar linear chelate gadodiamide
(Omniscan, GE Healthcare, New York, NY). The mean
amount of gadodiamide administered intra-arterially was
44±15.5 ml (range 15–60 ml) or 0.24+0.12 mmol/kg
(range 0.1–0.53 mmol/kg). One patient received 35 ml
(0.23 mmol/kg) of gadopentetate (gadolinium-DTPA;
Magnevist, Bayer Schering AG, Leverkusen, Germany)
and another patient received 20 ml (0.3 mmol/kg) of
gadobutrol (Gadovist 1.0 mmol/ml, Bayer Schering AG,
Leverkusen, Germany). Seventeen patients also received
CO2 besides GDBCA, and 13 patients were co-administered
with relatively small amounts of iodinated contrast material
(mean 14.3±16.7 ml, range 5–60 ml), including 8 patients
who received both CO2 and iodinated contrast material.
Additional MRI studies with GDBCA administration were
performed in 15 patients (Table 1).
At the time of angiography all patients had at least stage
3 renal insufficiency (eGFR <60 ml/min/1.73 m2). The
mean eGFR pre-angiography was 26.2±13.1 ml/
min/1.73 m2 (Table 2). According to the National Kidney
Foundation Kidney Disease Outcome Quality Initiative, 8
patients were stage 3, 13 stage 4, and 6 stage 5. The median
stage of disease was 4 (range 3–5). The mean ultimate
eGFR post-angiography (mean 28 months) was 33±
18.6 ml/min/1.73 m2. Mean sCr levels were 263.1±
128.7 µmol/l (range 134–728 µmol/l) pre-angiography,
288.2±154.7 µmol/l (range 125–764 µmol/l) 2 h post
angiography, 261.7±156.6 µmol/l (range 127–712 µmol/l)
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Table 1 Demographic and clinical data in 27 patients post-digital subtraction angiography with gadolinium-based contrast agents
(GDBCA)
No./sex Angiography
with GDBCA
Dose (ml)/type
of GDBCA
Additional MRI
with GDBCA
Dose (ml)/type
of GDBCA
Concurrent medical conditions at
time of angiography with GDBCA
1/F DSA and PTA lower extremity 35 Magnevist N/A N/A DM, AOD
2/M DSA lower extremity 50 Omniscan Abdomen 50 Omniscan AOD, CP, SCLC, DM, cvi
Head 20 Magnevist
3/M DSA lower extremity 20 Omniscan N/A N/A AOD, PPN, CU, CCP, COPD, GERD, BR
4/F DSA and PTA lower extremity 36 Omniscan N/A N/A AOD, sA, DM, CCP, COPD
5/F DSA and PTA lower extremity 36 Omniscan N/A N/A AOD, aHT, AS, HP, OP, SCS, NNA
6/F DSA and PTA lower extremity 20 Omniscan Renal 20 ProHance AOD, DM2, CCP, cP, A
7/M DSA and PTA lower extremity 20 Omniscan Renal 15 ProHance AOD, NI, CCP, IDP
Abdomen 30 Omniscan
8/F DSA abdomen 30 Omniscan Renal 25 Omniscan CS, cNI, CCP, DM, CVI, A
9/M DSA and PTA pelvis and
lower extremity
20 Omniscan Pelvis 20 ProHance ASCL, AOD, DM, COPD, NSCLC
Pelvis 20 Dotarem
Renal 30 Omniscan
Renal 30 Omniscan
Hip joint 20 Dotarem
Abdomen 50 Omniscan
10/M DSA and PTRA renal
transplant
15 Omniscan Head 15 Magnevist aHT, DM2, hCP, hc, Ac
Abdomen 20 ProHance
Renal 10 MultiHance
Abdomen 7 MultiHance
Abdomen 20 ProHance
Abdomen 30 Omniscan
Neck 15 Gadovist
Renal 30 Omniscan
Renal 30 Omniscan
11/M* DSA renal transplant 15 Omniscan Renal 30 ProHance hsm, ta, crf, aHT, HP, rA
Renal 30 Omniscan
Femur 30 ProHance
Renal 30 Omniscan
Renal 30 Omniscan
Renal 30 Omniscan
Renal 20 ProHance
Knee joint 10 Magnevist
12/M DSA pelvis and lower extremity 20 Omniscan Neck 15 Gadovist AOD, CCP, cNI, Hy
13/F DSA and PTA pelvis and
lower extremity
30 Omniscan N/A N/A AOD, MM, CCP, NNA, UC
14/M DSA and PTRA abdomen
and kidney
40 Omniscan Renal 30 Omniscan CoxA, HU, dCP, GITB, LR
15/M DSA lower extremity 20 Omniscan Renal 30 Omniscan CoSy, aHT, MI, PCA, TA, GIB, AAA, Tbc
16/F DSA and PTRA abdomen
and kidney
30 Omniscan Renal 30 ProHance aHT, rA, HP
Abdomen 30 ProHance
Abdomen 15 ProHance
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2 weeks post angiography, 310.3±179.5 µmol/l (range
122–592 µmol/l) 3 months post-angiography and final sCr
level after angiography was 247.1±181.8 µmol/l (range
78–880 µmol/l). The mean follow-up period was 28
(±29.5) months, range 1–84 months.
Dermatology reports were available for 11 patients.
Only one patient chart contained evidence of NSF. This
20-year old patient (no. 11 in Tables 1 and 2, patient data
summary in Table 3) was on dialysis from October 1998 to
August 2000. He received a renal transplant in August
2000, and dialysis was stopped. This patient had multiple
studies with GDBCA post-renal transplantation receiving
both linear and macrocyclic gadolinium-based contrast
agents (Table 3). The patient had to go back on dialysis in
May 2001. He observed skin changes and developed joint
pain in his knees, elbows and hands in September 2001,
which was approximately 5 months post-renal transplant
angiography with GDBCA. At the time, this patient had
received a total of 215 ml of GDBCA, including 135 ml
of linear and 80 ml of macrocyclic contrast agents. A skin
biopsy taken in late December 2001 was positive for NSF
in retrospect. Workup of this patient’s joint pain included
additional MRI studies of his thigh and knees with GDBCA
demonstrating synovial proliferation and periosteal in-
flammation. Macroscopic skin examination demonstrated
generally dry skin, nodules on the palms, calves and feet,
hyperpigmentation of both calves, and contracting finger
joints. A skin biopsy was obtained from the patient’s right
knee demonstrating thickening of the dermis and pro-
liferating fibroblasts compatible with NSF (Fig. 1).
Immunohistochemistry was positive for CD 34 and CD
68. This patient had also suffered from cardiac disease
(atrioventricular block) and eventually died of sudden
cardiac death in 2005.
In total, seven patients died, three of cardiac death, two
of natural causes, one died because the patient refused to
have dialysis and one died in an accident (a fall from a
cherry tree).
No./sex Angiography
with GDBCA
Dose (ml)/type
of GDBCA
Additional MRI
with GDBCA
Dose (ml)/type
of GDBCA
Concurrent medical conditions at
time of angiography with GDBCA
17/M DSA and PTRA abdomen
and kidney
20 Omniscan Head 20 Magnevist RAS, CCP, ATH, HP, aHT, REA
Renal 30 ProHance
18/M DSA and PTA pelvis 20 Gadovist Renal 30 Omniscan rA, aHT, HC, ATN, NNA, LC
Head 15 Magnevist
19/F DSA and PTA lower extremity 40 Omniscan N/A N/A N/A
20/M DSA and PTA abdomen
and lower extremity
90 Omniscan N/A N/A AOD, aHT, NI, LHI, CP, COPD
21/F DSA and PTA lower extremity 40 Omniscan Foot 8 Omniscan AOD, MNHL, HMA, Cni, D, Hy, cO, GA
Ankle joint 9 ProHance
Pelvis 30 Omniscan
22/M DSA abdomen 60 Omniscan N/A N/A crf, CCP, MI, pHT, AAA
23/F DSA and PTA lower extremity 20 Omniscan N/A N/A UC, DM2, dCP, PE, DVT, CVI
24/M DSA lower extremity 35 Omniscan N/A N/A CCP, MI, DM, Trf, EP
25/M DSA lower extremity 30 Omniscan N/A N/A DM, aHT, RCA
26/M DSA and PTRA abdomen
and kidney
50 Omniscan Abdomen 30 Magnevist CCP, AP, COPD, aHT, AOD, TIA, TURP
27/M DSA abdomen and pelvis 60 Omniscan N/A N/A ASKL, AOD
*This patient demonstrated NSF-typical skin changes that were biopsy-proven
Abbreviations:
A, adiposity; AAA, abdominal aortic aneurysm; Ac, acne; aHT, arterial hypertension; AOD, arterial occlusive disease; AP, angina pectoris; AS,
aortic stenosis; ASCL, arteriosclerosis; ATN, acute tubular necrosis; BR, Billroth’s stomach; CCP, coronary cardiopathy; COPD, chronic
obstructive pulmonary disease; CoSy, compartment syndrome M. triceps surae; CoxA, coxarthritis; CP, cardiopathy; cP, chronic pancreatitis;
crf, chronic renal failure; CS, carotid stenosis; CU, Cushing’s disease; cvi, cerebrovascular insult; CVI, chronic venous insufficiency; dCP,
dilatative cardiomyopathy; DM, diabetes mellitus; DVT, deep vein thrombosis; EP, encephalopathy; F, female; GDBCA, gadolinium-based
contrast agent; GERD, gastro-oesophageal reflux disease; GIB, gastrointestinal bleeding; HC, haemochromatosis; hc, hypercholesterinaemia;
HMA, hyperchromic macrocytic anaemia; HP, hyperparathyroidism; hsm, hepatosplenomegaly; HU, hyperuricaemia; Hy, hypothyreosis; IDP,
intervertebral disk prolapse; LC, lymphocele; LHF, left heart failure; LR, livedo racemosa; M, male; MI, myocardial infarction; MM, multiple
myeloma; MNHL, malignant non-Hodgkin’s lymphoma; N/A, not applicable; NNA, normochromic normocytic anaemia; NSCLC, non-small
cell lung cancer; OP, osteoporosis; PCA, prostatic cancer; PE, pulmonary embolus; pHT, pulmonary hypertension; PPN, peripheral
polyneuropathy; rA, renal anaemia; RAS, renal artery stenosis; RCA, rectal cancer; REA, reanimation, sA, septic arthritis; SCLC, small cell
lung cancer; SCS, spinal canal stenosis; ta, tachyarrhythmia; TA, temporal arteritis; Tbc, tuberculosis; TIA, transient ischaemic attack; Trf,
terminal renal failure; TURP, transurethral resection of the prostate; UC, ulcera cruris
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Discussion
In the present study we reviewed clinical and laboratory
data of 27 patients with renal insufficiency who underwent
conventional angiography using intra-arterial gadolinium-
based contrast agents (GDBCA) as alternate x-ray contrast
media and assessed the occurrence of nephrogenic sys-
temic fibrosis. Additional MRI studies with GDBCAwere
performed in 15 patients. Despite this rather high total
exposure to gadolinium-based contrast agents, only one
patient demonstrated NSF-typical skin changes that were
biopsy-proven. We cannot exclude further cases, but these
at least were not spontaneously reported or registered
within the clinical records.
It is well established that the use of iodinated contrast
material may cause contrast-induced nephropathy (CIN),
Table 2 Relevant laboratory values in 27 patients post-digital subtraction angiography with gadolinium-based contrast agents
No./sex sCr Level
(µmol/l) pre
sCr Level
(µmol/l) 2 h
sCr Level
(µmol/l)
1–2 weeks
sCr Level
(µmol/l)
3 months
sCr Level
(µmol/l)
ultimate#
eGFR
(ml/min/
1.73m2) pre
eGFR,
(ml/min/1.73m2)
post ultimate#
Chronic kidney
disease Stage*
1/F 413 428 NA 316 350 10 13 5
2/M 292 285 269 NA 269 19 23 4
3/M 403 395 333 404 246 13 24 5
4/F 271 162 201 NA 201 16 23 4
5/F 162 170 NA NA 170 28 27 4
6/F 287 262 262 188 188 15 22 4
7/M 212 186 204 202 126 30 53 3
8/F 301 446 NA NA 446 17 9 4
9/M 162 224 136 144 112 43 63 3
10/M 175 194 211 154 245 42 33 3
11/M* 728 764 712 539 470 7 14 5
12/M 143 159 143 NA 149 45 42 3
13/F 188 125 NA NA 125 24 38 4
14/M 242 389 447 592 880 27 7 4
15/M 201 233 224 215 189 30 32 3
16/F 350 NA NA 470 78 14 74 5
17/M 408 NA NA 562 631 14 7 5
18/M 136 NA NA NA 132 53 53 3
19/F 266 NA NA 126 126 16 37 4
20/M 323 338 NA NA 329 17 17 4
21/F NA NA 127 NA 113 NA 42 NA
22/M 229 230 NA NA 251 27 25 4
23/F 177 NA NA NA 177 27 27 4
24/M 177 NA NA NA 308 36 18 3
25/M 144 197 129 122 109 44 59 3
26/M 317 NA 266 NA 140 18 45 4
27/M 134 NA NA NA 111 49 62 3
MEAN 263.1 288.2 261.7 310.3 247.1 26.2 32.9 3.8
MEDIAN 235.5 231.5 217.5 215 188 25.5 27 4
SD 128.7 154.7 156.6 179.5 181.8 13.1 18.5 0.7
MIN 134 125 127 122 78 7 7 3
MAX 728 764 712 592 880 53 63 5
*This patient demonstrated NSF-typical skin changes that were biopsy-proven
Based on National Kidney Foundation Kidney Disease Outcomes Quality Initiative: eGFR values for stage 1, >90 ml/min/1.73 m2; stage 2,
60–90 ml/min/1.73 m2; stage 3, 30–59 ml/min/1.73 m2; stage 4, 15–29 ml/min/1.73 m2; stage 5, <15 ml/min/1.73 m2
NA, Not available; M, male; F, female; SD, standard deviation; eGFR, estimated glomerular filtration rate
#Mean follow-up period was 28 months, range 1– 84 months
599
especially in patients with underlying renal insufficiency
[1]. Because GDBCA seemed to have a reduced nephrotox-
icity compared with iodinated agents, physicians were
encouraged to switch over to GDBCA [11]. However, it
was a previous misconception that the use of GDBCA was
safe in patients with underlying renal insufficiency [2]. The
Contrast Media Safety Committee (CMSC) of the European
Society of Urogenital Radiology (ESUR) did not approve
GDBCA for radiographic examinations [3]. It was stated that
GDBCA should not be used for radiographic examinations
in patients with renal impairment and that these contrast
agents are more nephrotoxic than iodinated contrast in
equivalent radiographic attenuating doses.
In a previous study, GDBCAs were used to perform
digital subtraction angiography and percutaneous treatment
of renal artery stenosis in such patients [4]. Although
contrast-induced nephropathy potentially occurred in no
more than 3.2% of patients in this study, recent findings
indicate that these patients may be at increased risk of NSF.
In our study, all patients had an alteration of renal
function. As reported by Sadowski et al., a combination of
factors, including altered renal function, chronic inflam-
mation and exposure to gadolinium-based contrast agents,
may all play a role in the development of NSF [12]. In their
study, data of 13 patients with biopsy-confirmed NSF were
reviewed, and associated risk factors were assessed. All
patients had been exposed to GDBCAwithin a time frame
of 6 months. All patients had renal insufficiency and had
been hospitalised for a proinflammatory event such as
surgery, infection or a vascular event. Compared with a
control group, these patients had significantly decreased
eGFR, more proinflammatory events and more MRI studies
with GDBCA. In our study, conventional arterial angiogra-
phy was performed, which represents a proinflammatory
element that basically increases the risk of NSF. Furthermore,
GDBCA was administered intra-arterially for conventional
angiography. This implies higher renal first-pass toxicity
compared with IVadministration, especially if selective renal
artery angiography was performed.
Nephrogenic systemic fibrosis occurring in patients with
kidney impairment was lately reported to present with
characteristic skin manifestation and joint disease [5, 13,
14]. Previous literature reports describe coherence between
the use of gadolinium-based contrast agents and NSF [8–
10, 15–17]. In our study, one patient demonstrated skin
lesions characteristic of NSF, which was biopsy-proven.
There was a hiatus of approximately 5 months between his
renal transplant angiography with GDBCA and the onset of
symptoms, which seems rather long according to the
European Society of Urogenital Radiology (ESUR) guide-
lines, defining 8 weeks as the standard critical period [18].
As mentioned earlier, this patient had received as much as
135 ml of linear GDBCA before the onset of symptoms. It
remains uncertain if NSF was caused by the single-dose of
GDBCA administered during catheter angiography, while
the renal impairment was almost complete or the ones
given earlier for several MRI studies of the patient’s kidney
and thigh or the total amount of gadolinium during the
patient’s life-time. However, the cumulative dose of
GDBCA seems to be more likely responsible for the
onset of NSF than a single dose of 15 ml administered
during angiography [19].
We propose that there may be a possibility that repeated
GDBCA administration, as in our case, increased the risk
of NSF occurring in terms of an additive effect in GDBCA
deposition [10, 19, 20]. Furthermore, Abraham et al.
investigated retained gadolinium-containing deposits in
skin biopsies from 20 patients with gadolinium-related
NSF [21]. Of interest, gadolinium concentration increased
over time with multiple sequential biopsies in more than
Table 3 Data compilation of a 20-year old patient with glomeru-
lonephritis and tubulointerstitial nephritis. The patient was on
dialysis from October 1998 to August 2000. He received a renal
transplant in August 2000, and dialysis was stopped. The patient
underwent multiple MRA studies with GDBCA post-renal trans-
plantation receiving both linear and macrocyclic gadolinium-based
contrast agents. The patient was examined on 17 April 2001 for
conventional angiography with 15 ml of intra-arterial gadodiamide.
He had to go back on dialysis in May 2001. He observed skin
changes and developed joint pain in September 2001. At the time,
the patient had received a total of 215 ml of GDBCA, 135 ml of
linear and 80 ml of macrocyclic contrast agents. A skin biopsy taken
in late December 2001 was positive for NSF in retrospect
Date Study Type of GDBCA Structure of GDBCA Amount of GDBCA Creatinine (µmol/l) eGFR (ml/min/1.73m2)
11.08.00 MRI renal ProHance macrocyclic 30 ml 598 10
22.08.00 MRI renal Omniscan linear 30 ml 607 10
04.09.00 MRI thigh ProHance macrocyclic 30 ml NA NA
21.09.00 MRI renal Omniscan linear 30 ml NA NA
23.11.00 MRI renal Omniscan linear 30 ml 617 10
10.04.01 MRI renal Omniscan linear 30 ml NA NA
17.04.01 Angio renal transplant Omniscan linear 15 ml 728 7
24.12.01 MRI renal ProHance macrocyclic 20 ml 725 8
26.03.03 MRI knee Magnevist linear 10 ml 660 9
GDBCA, gadolinium-based contrast agent; NA, not available; eGFR, estimated glomerular filtration rate
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50% of patients for 23 months; after that a rather slow
decrease was observed reflecting the difficulty in eliminat-
ing the gadolinium once it is deposited in the tissues. The
authors suggested that gadolinium may be mobilised over
time from bone stores, explaining the variably delayed
onset of NSF.
The liberation of toxic and insoluble gadolinium after
dechelation following transmetallation of the gadolinium
chelate is the proposed trigger for NSF [8]. Free gadolin-
ium ions are released from the chelate in exchange for
endogenous metals, protons and subsequently form insol-
uble phosphates or hydroxides in the peripheral human
tissues. The precipitating gadolinium salts are engulfed by
circulating macrophages that attract fibrocytes. Because of
the relatively high capacity of solubilisation within the
lysosomes of the macrophages, these cells are probably
intoxicated, leading to a vicious circle. Because of a
markedly prolonged clearance and circulation time of
GDBCA in patients with end-stage renal disease, these
patients are at increased risk of NSF development. Mainly
two types of GDBCA chelates, linear open-chain and
macrocyclic ones, are commercialised. They differ in their
thermodynamic stability ratios expressed at different pH
values and velocity of decomplexation when under com-
petition from other protons or electrolytes. Linear chelates,
such as gadodiamide (Omniscan), which was mainly used
for angiography in our study because of its rather low
osmolality of 780 mOsm/kg H2O at 37°C, seem to be at
Fig. 1 Skin biopsy specimen obtained from patient’s right knee. a,
Biopsy (haematoxylin and eosin) with low magnification demon-
strates thickening of the dermis (arrow) with haphazardly arranged
collagen bundles separated by large clefts in the papillary and deep
dermis. Spindled fibroblasts extend into subcutaneous septae
(asterisk). b High magnification with an increased number of
spindled fibroblasts. Collagen bundles are separated by large clefts
(asterisk). c High magnification (immunohistochemical stain with
CD 68) demonstrates positive stellate fibroblast cells (arrow). d
High magnification (immunohistochemical stain with CD 34)
demonstrates fibroblast reactivity
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higher risk of decomplexation than macrocylic chelates
such as gadoteridol (ProHance). A summary of the medical
literature reports more than 90% of NSF cases associated
with GDBCA administration related to gadodiamide
(Omniscan) [22]. Thomsen et al. report the prevalence of
NSF to be significantly higher post-gadodiamide than any
other gadolinium-based agent (3–7% versus 0–1% per
injection) in patients with reduced renal function [17].
After exposure to two gadodiamide injections, they found
prevalence as high as 36% in patients with chronic kidney
disease stage 5. In the current literature, no reports of NSF
after the administration of most stable agents have been
published, implying that there may be a difference in
triggering NSF between various agents.
As the relationship of NSF with the administration of
GDBCAwas unknown at the time, absurdly, additional MRI
studies with gadolinium-based contrast agents were per-
formed working up our patient’s symptoms and following up
the renal transplant. Despite the nebulosity of NSF at the time,
in our positive case a skin biopsy was obtained, and
histopathology was reported to demonstrate dermal fibrosis,
thickening of the dermis and proliferating fibroblasts. With
today’s knowledge, these findings are compatible with NSF.
Immunohistochemistry was not performed at the time, but we
were able to obtain the original tissue specimen and produced
additional stains using immunohistochemistry for CD 34 and
CD 68, which were characteristically positive for NSF.
There are several limitations of this study. First, the
study is retrospective and therefore not controlled for
selection bias, detection of events and data collection.
Second, although 27 patients were studied, adverse events
that occur at a low rate or that were of rather weak intensity
could have been missed or were underreported. Moreover,
different types of GDBCA were used in our study, further
decreasing the potential sensitivity of the study for adverse
events and correlation of GDBCA with outbreaks of NSF.
Third, because of the retrospective design of this study,
signs for NSF could have been missed in individual
patients because data were missing and because NSF had
not been recognised during the entire study period
included.
In conclusion, exposition with gadolinium-based con-
trast agents during conventional angiography may play a
role in the development of NSF in patients with renal
insufficiency. Alternative contrast agents such as CO2
angiography or rather the use of low doses of iodinated
contrast agents should be considered in these patients.
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